DivestmentJul 15, 2026, 07:36 AM
Senti Biosciences Divests SENTI-202 Pipeline; Focuses on Regulator Dial
AI Summary
Senti Biosciences Holdings, Inc. announced a strategic transaction to divest substantially all of its existing business and pipeline, including SENTI-202, to a private affiliate of its largest stockholder, Celadon Partners. The company will remain public, streamlining its operations to focus on its Regulator Dial™ technology platform, including programs for Rett syndrome and TIL therapies. Stockholders will receive Contingent Value Rights (CVRs) that could provide up to $60 million in future cash payments based on SENTI-202 development, regulatory, and commercial milestones.
Key Highlights
- Divests existing business and SENTI-202 pipeline to a private affiliate of Celadon Partners.
- Senti Biosciences Holdings (SBH) to remain public, focusing on Regulator Dial™ technology platform.
- SBH stockholders to receive Contingent Value Rights (CVRs) for SENTI-202 milestones.
- CVRs offer up to $60 million in potential milestone payments over a seven-year period.
- Milestones include $10 million for BLA filing and $20 million for FDA approval of SENTI-202.
- An additional $30 million is tied to achieving $200 million in cumulative net sales of SENTI-202.
- Transaction is subject to stockholder approval and other customary closing conditions.
- Remaining SBH programs are early-stage Rett Syndrome and armored TIL therapies.
Price Impact
More from SNTI